Combined inhibition of MS4A4A and PD-1 has demonstrated substantial antitumor efficacy in drug-resistant CRC, significantly delaying tumor progression and indicating its potential as a novel immunotherapeutic approach [141]. This evidence concerns the gene PDCD1 and colorectal carcinoma.